(19)
(11) EP 3 260 117 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
27.11.2019 Bulletin 2019/48

(45) Mention of the grant of the patent:
17.04.2019 Bulletin 2019/16

(21) Application number: 17185704.8

(22) Date of filing: 10.09.2004
(51) International Patent Classification (IPC): 
A61K 31/135(2006.01)
A61K 9/20(2006.01)
 A61K 9/28(2006.01)
A61P 5/18(2006.01)

(54)

RAPID DISSOLUTION FORMULATION COMPRISING CINACALCET HCL

SCHNELLAUFLÖSUNGSFORMULIERUNG ENTHALTEND CINACALCET HCL

FORMULATION À DISSOLUTION RAPIDE DE CINACALCET HCL

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30) Priority: 12.09.2003 US 502219 P

(43) Date of publication of application:
27.12.2017 Bulletin 2017/52

(60) Divisional application:
18175495.3 / 3395338
18175497.9 / 3395339
18175499.5 / 3395340
19164145.5

(62) Application number of the earlier application in accordance with Art. 76 EPC:
14163366.9 / 2821067
10014567.1 / 2316442
04781429.8 / 1663182

(73) Proprietor: Amgen Inc.
Thousand Oaks, CA 91320-1799 (US)

(72) Inventors:
  • ÁLVAREZ, Francisco J.
    Newbury Park, CA California 91320 (US)
  • JU, Tzuchi R.
    Vernon Hills, IL Illinois 60061 (US)
  • LIN, Hung-Ren H.
    Oak Park, CA California 91377 (US)
  • LAWRENCE, Glen Cary
    Thousand Oaks, CA California 91320-1799 (US)

(74) Representative: EIP 
EIP Europe LLP Fairfax House 15 Fulwood Place
London WC1V 6HU
London WC1V 6HU (GB)


(56) References cited: : 
US-B1- 6 211 244
   
  • GOODMAN WILLIAM G ET AL: "The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY : JASN. APR 2002, vol. 13, no. 4, April 2002 (2002-04), pages 1017-1024, XP002313387, ISSN: 1046-6673
  • ANONYMOUS: "Amgen submitted new drug application for Cinacalcet HCI", AMGEN NEWS RELEASE , 8 September 2003 (2003-09-08), XP002313388, Retrieved from the Internet: URL:http://www.amgen.com/news/news03/press Release030908a.pdf [retrieved on 2005-01-12]
  • ANONYMOUS: "FDA Approves First in a New Class of Drugs to Treat Hyperparathyroidism Associated With Renal Failure and in Patients With Parathyroid Cancer", FDA TALK PAPER , 8 March 2004 (2004-03-08), XP002313389, Retrieved from the Internet: URL:http://www.fda.gov/bbs/topics/ANSWERS/ 2004/ANS01282.html [retrieved on 2005-01-11]
  • ANONYMOUS: "Sensipar (cinacalcet HCI) Tablets", INTERNET ARTICLE , 12 August 2004 (2004-08-12), XP002313390, Retrieved from the Internet: URL:www.rxlist.com/cgi/generic3/sensipar.h tm [retrieved on 2005-01-10]
  • NEMETH EDWARD F ET AL: "Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. FEB 2004, vol. 308, no. 2, February 2004 (2004-02), pages 627-635, XP009042339, ISSN: 0022-3565
  • "Cinacalcet: AMG 073, Calcimimetics--Amgen/NPS Pharmaceuticals, KRN 1493, NPS 1493.", DRUGS IN R&D. 2003, vol. 4, no. 6, 2003, pages 349-351, XP009042342, ISSN: 1174-5886
  • ANONYMOUS: "NPS-Drug Development: Product Develpment Pipeline", INTERNET ARTICLE , 8 September 2003 (2003-09-08), XP002313391, Retrieved from the Internet: URL:www.npsp.com/drug_development/pipeline .php [retrieved on 2005-01-12]
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).